Target
Secretory leukocyte protease inhibitor
Description
ADCC-Enhanced anti-Secretory leukocyte protease inhibitor (42C1) is a non-fucosylated therapeutic biobetter antibody engineered by Creative Biolabs' Afuco™ technology platform.
Antibody Indication
Cancer
Classification
Therapeutic antibody; biobetter
Cooperation Seeking
Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced Secretory leukocyte protease inhibitor antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Full Name
secretory leukocyte peptidase inhibitor
Background
This gene encodes a secreted inhibitor which protects epithelial tissues from serine proteases. It is found in various secretions including seminal plasma, cervical mucus, and bronchial secretions, and has affinity for trypsin, leukocyte elastase, and cathepsin G. Its inhibitory effect contributes to the immune response by protecting epithelial surfaces from attack by endogenous proteolytic enzymes. This antimicrobial protein has antibacterial, antifungal and antiviral activity.
Alternative Names
SLPI; secretory leukocyte peptidase inhibitor; ALP; MPI; ALK1; BLPI; HUSI; WAP4; WFDC4; HUSI-I; antileukoproteinase; HUSI-1; protease inhibitor WAP4; mucus proteinase inhibitor; seminal proteinase inhibitor; WAP four-disulfide core domain protein 4; secretory leukocyte protease inhibitor (antileukoproteinase)
Cellular Localization
Extracellular region or secreted
Involvement in Disease
Diseases associated with SLPI include Renal Osteodystrophy and Pustular Psoriasis.
Related Pathways
Its related pathways are Innate Immune System.
Function
An acidic stable protease inhibitor with strong affinity for trypsin, chymotrypsin, elastase and cathepsin G. Regulate inflammation and immune response after bacterial infection, and after infection of intracellular parasite L. major. Down-regulate the response to bacterial lipopolysaccharide (LPS) (similarity). Participate in the regulation of nf-kpa-b activation and inflammation. It has antibacterial activity against mycobacteria, but has no effect on Salmonella. Contribute to the normal resistance to tuberculosis infection. Need to have normal resistance to L.major infection. It is necessary for normal wound healing to prevent tissue damage by limiting protease activity (similarity). Together with ELANE required for normal differentiation and proliferation of bone marrow cells.
Field of research
Cell Biology and Cellular Response antibody; Immune System antibody
Post-translational modifications
1.Modification sites at neXtProt 2.Modification sites at PhosphoSitePlus
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Description
The fully human monoclonal antibody against secretory leukocyte protease inhibitor (SLPI) expressed in respiratory epithelium and also in a variety of cancers including lung, breast, oropharyngeal, bladder, ovarian, endometrial and colorectal. SLPI expression has been correlated with tumor progression.
Antibody Indication
Cancer
